IL279924B2 - Generating cik nkt cells from cord blood - Google Patents

Generating cik nkt cells from cord blood

Info

Publication number
IL279924B2
IL279924B2 IL279924A IL27992421A IL279924B2 IL 279924 B2 IL279924 B2 IL 279924B2 IL 279924 A IL279924 A IL 279924A IL 27992421 A IL27992421 A IL 27992421A IL 279924 B2 IL279924 B2 IL 279924B2
Authority
IL
Israel
Prior art keywords
cells
nkt cells
cell
population
cer
Prior art date
Application number
IL279924A
Other languages
English (en)
Hebrew (he)
Other versions
IL279924B1 (en
IL279924A (en
Inventor
Rohit Duggal
Ranjeet Sinha
Original Assignee
Immunitybio Inc
Rohit Duggal
Ranjeet Sinha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc, Rohit Duggal, Ranjeet Sinha filed Critical Immunitybio Inc
Publication of IL279924A publication Critical patent/IL279924A/en
Publication of IL279924B1 publication Critical patent/IL279924B1/en
Publication of IL279924B2 publication Critical patent/IL279924B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL279924A 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood IL279924B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696131P 2018-07-10 2018-07-10
PCT/US2019/040145 WO2020014029A1 (en) 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood

Publications (3)

Publication Number Publication Date
IL279924A IL279924A (en) 2021-03-01
IL279924B1 IL279924B1 (en) 2025-04-01
IL279924B2 true IL279924B2 (en) 2025-08-01

Family

ID=67551410

Family Applications (2)

Application Number Title Priority Date Filing Date
IL279924A IL279924B2 (en) 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood
IL319500A IL319500A (en) 2018-07-10 2019-07-01 Production of CIK NKT cells from cord blood

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL319500A IL319500A (en) 2018-07-10 2019-07-01 Production of CIK NKT cells from cord blood

Country Status (9)

Country Link
US (2) US11931382B2 (enExample)
EP (1) EP3820994A1 (enExample)
JP (3) JP7190022B2 (enExample)
KR (3) KR102778139B1 (enExample)
CN (2) CN119372142A (enExample)
AU (2) AU2019300782B2 (enExample)
CA (1) CA3105601C (enExample)
IL (2) IL279924B2 (enExample)
WO (1) WO2020014029A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174529A1 (en) * 2020-03-04 2021-09-10 Bioeclipse Therapeutics, Inc. Methods of manufacturing activated immune cells
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
CN111690607B (zh) * 2020-06-19 2022-02-18 珠海贝索细胞科学技术有限公司 一种高效杀伤细胞体外培养试剂盒及培养方法
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170029777A1 (en) * 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
US20170042939A1 (en) * 2015-08-13 2017-02-16 Tsinghua University Nkt-like cell subpopulation and method of using the same in the treatment of tumor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
BR9813981A (pt) 1997-11-06 2000-09-26 Roche Diagnostics Gmbh Antìgenos de tumor especìficos, métodos para a sua produção e seu uso imunização de diagnóstico
EP1117691A1 (en) 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
KR20030032961A (ko) * 2000-06-06 2003-04-26 기린 비루 가부시키가이샤 내츄럴 킬러 ｔ 세포의 증폭 방법
WO2005014008A2 (en) * 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
WO2011052638A1 (ja) 2009-10-28 2011-05-05 タカラバイオ株式会社 サイトカイン誘導キラー細胞の製造方法
AU2010347018A1 (en) * 2010-02-24 2012-09-20 Ingo Schmidt-Wolf Method for the generation of a CIK cell and NK cell population
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
US20150225697A1 (en) 2012-08-13 2015-08-13 Anthrogenesis Corporation Natural killer cells and uses thereof
DK2893004T3 (en) 2012-09-04 2019-02-04 Cellectis MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
CN104017770B (zh) * 2014-06-23 2015-04-29 山东赛乐中德生物科技有限公司 一种利用糖脂制备cik细胞的方法
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN105176927B (zh) * 2015-10-15 2019-01-18 丛秀丽 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法
CN106566807A (zh) * 2016-10-21 2017-04-19 闾军 一种浓度梯度rhIL‑2依赖的iNKT细胞扩增方法及其应用
CN106434556B (zh) * 2016-11-22 2019-10-11 上海新长安生物科技有限公司 一种体外诱导扩增i型nkt细胞的方法
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CN114258305A (zh) * 2019-08-21 2022-03-29 阿克索治疗公司 Iii型nkt细胞及相关组合物和方法
CN111172110B (zh) * 2019-12-20 2022-04-22 中科细胞科技(广州)有限公司 一种脐带血cik细胞的培养方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170029777A1 (en) * 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
US20170042939A1 (en) * 2015-08-13 2017-02-16 Tsinghua University Nkt-like cell subpopulation and method of using the same in the treatment of tumor

Also Published As

Publication number Publication date
US20220347218A1 (en) 2022-11-03
KR20210028675A (ko) 2021-03-12
JP7190022B2 (ja) 2022-12-14
CA3105601C (en) 2024-01-16
JP2023012503A (ja) 2023-01-25
IL279924B1 (en) 2025-04-01
JP7664207B2 (ja) 2025-04-17
CN112424343B (zh) 2024-10-22
IL279924A (en) 2021-03-01
AU2024200673A1 (en) 2024-03-07
KR20230133942A (ko) 2023-09-19
IL319500A (en) 2025-05-01
EP3820994A1 (en) 2021-05-19
CN119372142A (zh) 2025-01-28
US11931382B2 (en) 2024-03-19
KR102778139B1 (ko) 2025-03-10
KR102721222B1 (ko) 2024-10-24
AU2019300782A1 (en) 2021-01-14
AU2019300782B2 (en) 2023-12-21
KR102577954B1 (ko) 2023-09-14
JP2025015816A (ja) 2025-01-30
JP2021530224A (ja) 2021-11-11
CA3105601A1 (en) 2020-01-16
US20240180967A1 (en) 2024-06-06
KR20240154707A (ko) 2024-10-25
CN112424343A (zh) 2021-02-26
WO2020014029A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL279924B2 (en) Generating cik nkt cells from cord blood
Wang et al. Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell–NK cell axis in murine hepatocellular carcinoma model
Motohashi et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non–small cell lung cancer
Xu et al. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect
Shoji et al. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models
KR20100083838A (ko) 의약 조성물 및 의약 조성물의 제조방법
US11351196B2 (en) Generating CIK NKT cells from cord blood
Guo et al. Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients
Asl et al. Intra-lesion injection of activated Natural Killer (NK) cells in recurrent Malignant brain tumors
NZ555571A (en) Alpha thymosin peptides as cancer vaccine adjuvants
Chan et al. Chimeric antigen receptor (CAR)-T cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review
Buchsel et al. Dendritic cells: emerging roles in tumor immunotherapy
US20190231822A1 (en) Methods of reducing chronic graft-versus-host disease
Wang et al. Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma
CN118652343B (zh) 一种临床血液免疫细胞以及在治疗疾病中的应用
Zhao et al. Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Asl et al. The Safety and Feasibility of Intra Surgical Cavity or intra Cerebrospinal Fluid (CSF) Injection of Haploidentical Activated NK Cells in Patients with Recurrent Glioblastoma Multiforme and Brain Tumors
Lwin et al. Immune-cell-mediated cancer treatment: advantages, drawbacks and future direction.
CN121041428A (zh) 组合物及其在制备抗肿瘤药物中的应用
Ni et al. Chimeric antigen receptor-T cell, a novel player in anti-tumor treatment
EP2875827A1 (en) Preparations and methods for treating a GD2 positive cancer